Show simple item record

dc.contributor.authorCalifano, Raffaele
dc.contributor.authorHochmair, MJ
dc.contributor.authorGridelli, C
dc.contributor.authorDelmonte, A
dc.contributor.authorCampelo, MRG
dc.contributor.authorBearz, A
dc.contributor.authorGriesinger, F
dc.contributor.authorMorabito, A
dc.contributor.authorFelip, E
dc.contributor.authorGhosh, S
dc.contributor.authorTiseo, M
dc.contributor.authorHaney, J
dc.contributor.authorKerstein, D
dc.contributor.authorPopat, S
dc.contributor.authorCamidge, DR
dc.date.accessioned2019-10-04T09:48:23Z
dc.date.available2019-10-04T09:48:23Z
dc.date.issued2019en
dc.identifier.citationCalifano R, Hochmair MJ, Gridelli C, Delmonte A, Garcia Campelo MR, Bearz A, et al. 106O Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol. 2019;30(Supplement_2):41.en
dc.identifier.doi10.1093/annonc/mdz063.004en
dc.identifier.urihttp://hdl.handle.net/10541/622099
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz063.004en
dc.titleBrigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T13:21:40Z


Files in this item

Thumbnail
Name:
561993.pdf
Size:
63.19Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record